{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:49:46Z","timestamp":1791974986077,"version":"4.4.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n \n Antibody-drug conjugates (ADCs), such as trastuzumab emtansine and trastuzumab deruxtecan, are effective in treating erb-b2 receptor tyrosine kinase 2 (\n ERBB2<\/jats:italic>\n )\u2013positive breast cancer (BC) that has progressed on prior\n ERBB2<\/jats:italic>\n -targeted therapy, warranting evaluation of their cardiotoxic profiles.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To compare the incidence of cardiotoxic effects of ADCs vs standard-of-care chemotherapy regimens for\n ERBB2<\/jats:italic>\n -positive locally advanced or metastatic BC.\n <\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, ScienceDirect, Cochrane Library, and ClinicalTrials.gov databases were searched in December 2024 for studies published between 2000 and 2024.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n \n The included studies were (1) phase 3 clinical trials that investigated locally advanced or metastatic\n ERBB2<\/jats:italic>\n -positive BC; (2) clearly defined left ventricular ejection fraction (LVEF) decrease or heart failure definitions; (3) clearly defined LVEF monitoring frequency by echocardiography or multigated acquisition scan; (4) included studies consisted solely of either trastuzumab emtansine, trastuzumab deruxtecan, or one of the first-line to fourth-line chemotherapy regimens for unresectable stage IV\n ERBB2<\/jats:italic>\n -positive breast cancer per the 2025 National Comprehensive Cancer Network guidelines; and (5) clearly defined cardiovascular eligibility criteria.\n <\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Data from eligible studies were extracted by 3 reviewers. A random-effects model was used for the pooled analysis. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was followed.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was cardiotoxic effects, which were defined as the incidence of LVEF decrease. The pooled analysis was performed using logit-transformed proportions with the inverse variance method and a DerSimonian-Laird random-effects model for between-study variance, with Wilson score 95% CIs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In this meta-analysis of 9538 patients, a pooled analysis demonstrated a 0.94% (95% CI, 0.56%-1.57%) incidence of LVEF decrease with trastuzumab emtansine, a 4.20% (95% CI, 2.91%-6.01%) incidence with trastuzumab deruxtecan, a 4.85% (95% CI, 3.73%-6.28%) incidence with trastuzumab plus chemotherapy, and a 5.52% (95% CI, 3.41%-8.83%) incidence with trastuzumab plus pertuzumab plus chemotherapy. A trim-and-fill analysis was used if evidence of publication bias was found.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This meta-analysis found that trastuzumab emtansine was associated with the lowest incidence of LVEF decrease, and trastuzumab deruxtecan, trastuzumab plus chemotherapy, and trastuzumab plus pertuzumab plus chemotherapy had similar incidences. More research is needed into the cardiotoxic effects of these therapies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.40336","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T13:00:17Z","timestamp":1764680417000},"page":"e2540336","source":"Crossref","is-referenced-by-count":11,"title":["Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in\n ERBB2<\/i>\n -Positive Advanced Breast Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Lakshya","family":"Seth","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bhave","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Kollapaneni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Nahle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Blaes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Hurvitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Augusta"},{"name":"Cardio-Oncology Program, Department of Medicine, Cardiology Division, Medical College of Georgia at Augusta University, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"issue":"1","key":"zoi251109r1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi251109r2","first-page":"40","article-title":"HER2-positive metastatic breast cancer: a comprehensive review.","volume":"19","author":"Exman","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10087","key":"zoi251109r3","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer.","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"zoi251109r4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions.","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"zoi251109r5","doi-asserted-by":"publisher","first-page":"vii36","DOI":"10.1093\/annonc\/mdq421","article-title":"Treatment of HER2-overexpressing breast cancer.","volume":"21","author":"Baselga","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi251109r6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi251109r7","doi-asserted-by":"publisher","first-page":"14312","DOI":"10.1038\/s41598-022-18342-1","article-title":"Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer.","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"zoi251109r8","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854","article-title":"Trastuzumab-associated cardiotoxicity.","volume":"95","author":"Keefe","year":"2002","journal-title":"Cancer"},{"issue":"14","key":"zoi251109r9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer.","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi251109r10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy.","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"zoi251109r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108106","article-title":"Antibody-drug conjugates: resurgent anticancer agents with multi-targeted therapeutic potential.","volume":"236","author":"Ceci","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"6","key":"zoi251109r12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"zoi251109r13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer.","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"10390","key":"zoi251109r14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"zoi251109r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations.","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"zoi251109r16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"zoi251109r18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"3","key":"zoi251109r19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"11","key":"zoi251109r20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"zoi251109r22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10549-024-07417-4","article-title":"A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2\/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).","volume":"207","author":"Mezzanotte-Sharpe","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"zoi251109r23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10549-021-06197-5","article-title":"Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.","volume":"188","author":"Rugo","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"zoi251109r24","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1002\/cncr.32392","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE.","volume":"125","author":"Perez","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"zoi251109r25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"zoi251109r26","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.2014.56.9590","article-title":"Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31.","volume":"33","author":"Gelmon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi251109r27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40259-021-00513-7","article-title":"Long-term safety and effectiveness of PF-05280014 (a trastuzumab biosimilar) treatment in patients with HER2-positive metastatic breast cancer: updated results of a randomized, double-blind study.","volume":"36","author":"Li","year":"2022","journal-title":"BioDrugs"},{"issue":"2","key":"zoi251109r28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","article-title":"Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.","volume":"29","author":"Valero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi251109r29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1200\/JCO.21.02937","article-title":"Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial.","volume":"41","author":"Rugo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"zoi251109r30","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/JCO.2016.70.6267","article-title":"Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy.","volume":"35","author":"Urruticoechea","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi251109r31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-009-0498-7","article-title":"Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.","volume":"119","author":"Inoue","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi251109r32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.clbc.2019.02.008","article-title":"Results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE).","volume":"19","author":"Woodward","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"zoi251109r33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi251109r34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10549-021-06145-3","article-title":"Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: final analysis of MetaPHER, a phase IIIb single-arm safety study.","volume":"187","author":"Kuemmel","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi251109r35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","article-title":"Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.","volume":"18","author":"Swain","year":"2013","journal-title":"Oncologist"},{"issue":"3","key":"zoi251109r36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10549-020-05728-w","article-title":"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.","volume":"182","author":"Xu","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"zoi251109r37","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"zoi251109r38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","article-title":"Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1.","volume":"109","author":"Montemurro","year":"2019","journal-title":"Eur J Cancer"},{"issue":"10371","key":"zoi251109r39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"17","key":"zoi251109r40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1008","article-title":"Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2\u2013positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): interim results from DESTINY-Breast09.","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi251109r41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi251109r42","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer.","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"zoi251109r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer.","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"zoi251109r44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"1","key":"zoi251109r45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jclinepi.2007.03.016","article-title":"The binomial distribution of meta-analysis was preferred to model within-study variability.","volume":"61","author":"Hamza","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"zoi251109r17","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. 2025. Accessed March 4, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"zoi251109r21","unstructured":"R Core Team. R: A language and environment for statistical computing. Accessed September 26, 2025. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2841247\/seth_2025_oi_251109_1762286533.37389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T13:00:18Z","timestamp":1764680418000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2841247"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.40336","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]}}}